Drug Discovery · New Haven, CT · Founded 2019 · Publicly Held
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. VeraDermics (NYS: MANE) is based in New Haven, CT and was founded in 2019. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $596 million (Feb 2026). It has raised $519 million across 1 recorded round; the latest was a $150 million Series C in Oct 2025.
Last price · $/share
—
Implied valuation
$596.3M
Total raised
$518.6M
Last round
Later Stage VC (Series C)
Oct 2025
Team — not yet on record
No current team members for VeraDermics (NYS: MANE) are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of VeraDermics (NYS: MANE) with a free account
·The complete investor list: 26 names
·Watch VeraDermics (NYS: MANE): the Monday email on marks, rounds and moves
